Cisplatin-induced ototoxicity is a detrimental side effect of chemotherapy leading to hearing loss, for which no treatments are currently available. Despite …
Investigating the Synergistic Effect of the Cannabis Extract PHEC-66 and Chemotherapeutic Agents on Human Melanoma Cells.
Melanoma is a malignant neoplasm that originates from melanocytes. It continues to pose a significant challenge in oncology due to its aggressive nature and …
Delta-9-Tetrahydrocannabinol alleviates doxorubicin-induced weight loss but does not affect dextran sodium sulphate-induced colitis.
Gastrointestinal mucositis is a common adverse effect of chemotherapy. Inflammatory bowel diseases (IBD) are a spectrum of chronic inflammatory disorders of …
Targeting molecular pathways in neuropathic cancer pain: from mechanisms to novel therapeutics.
Neuropathic cancer pain (NCP) remains a formidable clinical adversary, severely compromising the quality of life for cancer survivors. Its pathogenesis is hi…
Australian Trial to Test Medicinal Cannabis Against Chemotherapy’s Gut Side Effects
“There are currently no effective approved interventions to prevent gastrointestinal symptom clusters in people undergoing cytotoxic cancer therapy.”
Australian Trial to Test Whether Cannabis Can Prevent Chemotherapy Gut Damage: Protocol Published
There are currently no effective approved interventions to prevent gastrointestinal symptom clusters in people undergoing cytotoxic cancer therapy. The CANCAN trial will investigate the efficacy of medicinal cannabis in controlling GI-M and the constellation of impactful symptoms in people with advanced cancer.
Cannabinoids in Combination with Conventional Breast Cancer Therapies: Mechanistic Insights and the Gap to Clinical Translation.
Current treatments for breast cancer (BC) include surgery, radiation, chemotherapy, targeted therapy, hormonal therapy, and immunotherapy. However, adverse e…